New Approved First-line Combining Therapy of NSCLC in 2020

¹ School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China
² Southern University of Science and Technology Hospital, Shenzhen, Guangdong 518055, China
³ Department of Pharmaceutics and Pharmacy Administration, School of Pharmacy, Air Force Medical University, Xi’an, Shanxi 710032, China.

^* Corresponding author e-mail: wangyk@sustech.edu.cn

Abstract

In the past decades, lung cancer is considered one of the lethal cancers all across the world due to its evidenced greatest mortality and morbidity. Currently, the main clinical treatment methods for lung cancer involve surgery, chemotherapy, radiotherapy, anti-angiogenesis inhibitors and tyrosine kinase inhibitors. In the field of anticancer drugs, a variety of new anticancer drugs have been emerging in recent years. They include chemotherapy drugs with new delivery modes, targeted drugs for tyrosine kinase inhibitors, angiogenesis inhibitors, and immunotherapy drugs that have remained hot. But because cancer cells have complex escape mechanisms, the effectiveness of these single-drug treatments has been disappointing. In this case, a number of new combination therapies have emerged and achieved relatively good results. According to the 2020 third edition of the NCCN guidelines, four multi-therapy regiments (Erlotinib plus ramucirumab, Erlotinib plus bevacizumab, Carboplatin plus albumin-bound paclitaxel plus atezolizumab and Nivolumab plus ipilimumab) have passed clinical trials, adding first-line treatments. In this review, the research provided an overview of these four new approved combining treatment strategies in addition to predicting future drug development directions.